Summary#
This bill would require the Director of the National Institute of Allergy and Infectious Diseases (NIAID) to award a competitive grant for the Antibiotic Resistance Leadership Group (ARLG). The stated purpose is to help set up or support a clinical research network focused on antibiotic resistance. The bill also says it is “for other purposes,” but does not say what those are.
- Main change: directs NIAID to award a competitive grant for the ARLG to facilitate a clinical research network on antibiotic resistance.
- Who introduced it: Senators Maggie Hassan and Roger Marshall.
- Current stage: read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions.
- Scope: aims to support clinical research activities related to antibiotic resistance.
- Unclear point: the bill’s phrase “and for other purposes” is not explained in the available material.
What it means for you#
- Researchers and clinicians: The bill could channel federal grant money to a group focused on antibiotic resistance. This could support clinical trials, data sharing, or multi-site studies, but the bill text does not list specific activities.
- Patients: If the grant leads to more or better clinical studies, patients with drug-resistant infections might see faster testing of new treatment strategies. This is a possible outcome, not a guaranteed one.
- NIAID (federal research agency): The agency would be required to award the specified competitive grant. That could mean adjusting funding priorities or administering a new grant competition.
- Antibiotic Resistance Leadership Group (ARLG): The bill names this group as the grant recipient or beneficiary. That would likely increase its role in coordinating clinical research, if the grant is awarded as directed.
- Taxpayers: Public funds would be used for the grant, but no funding amount is given in the available material.
- Other federal or state health programs: The bill could create overlaps or require coordination with existing antibiotic-resistance initiatives, but the text does not explain how coordination would work.
Expenses#
No publicly available information.
- The bill text available here does not include a fiscal note or any dollar amounts.
- Likely costs could include the grant itself, administrative costs for NIAID to run the competition, and any follow-up oversight, but amounts are not specified.
- It is not clear whether funds would come from existing NIAID budgets or require new appropriations.
Proponents' View#
- The bill appears intended to strengthen clinical research on antibiotic resistance by supporting a dedicated research network.
- Supporters may argue that a focused, coordinated clinical research network could speed the testing and evaluation of new treatments or stewardship approaches.
- Directing funds to a named leadership group could help centralize expertise and improve multi-site clinical trials for resistant infections.
- Naming a competitive grant suggests an attempt to keep awarding through a formal competition rather than a sole-source transfer.
Opponents' View#
- One concern is that the bill names a specific group (the ARLG) while also directing a grant; even with the word “competitive,” it may raise questions about earmarking or fairness in grant-making.
- The bill does not state how much money is needed or where the funds would come from, making budget impacts unclear.
- It is unclear how this new network would fit with existing federal and private efforts on antibiotic resistance, possibly creating duplication or coordination problems.
- The phrase “and for other purposes” is vague and leaves important scope and implementation details unspecified.